证券代码：300194 证券简称：福安药业 公告编号：2025-026 福安药业（集团）股份有限公司 关于2025年中期现金分红预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第3 号 —— 上市公司现金分红》 及《公司章程》等规定，为充分考虑对投资者的回报，福安药业（集团）股份有限公司（以 下简称："公司"）于2025年8月26日召开第六届董事会第三次会议，会议审议通过《关 于2025年中期现金分红预案的议案》，该事项尚需经公司股东大会审议通过后实施，现将 有关事项公告如下： 一、2025 年中期现金分红预案 （一）基本情况 （2）公司拟订的 2025 年中期现金分红预案为： 以公司现有总股本 1,189,712,382 股为基数，向全体股东每 10 股派发现金股利 0.20 元人民币（含税），共计派发现金股利 23,794,247.64 元（含税）。不进行资本公积转增股 本，不送红股。 （3）截至本公告日，公司不存在股份回购情形。 （二）调整原则 如公司在实施权益分派的股权登记日前公司总股本发生变 ...

福安药业（集团）股份有限公司 2025 年半年度报告全文 福安药业（集团）股份有限公司 2025 年半年度报告 2025 年 8 月 1 福安药业（集团）股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证本 半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划、发展战略、经营计划等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 公司在本报告"第三节管理层讨论与分析"之第十部分"公司面临的风险和应对措施"详细描述了公司 经营中可能存在的风险，敬请投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 1,189,712,382 为基数，向全体股东每 10 股派发现 金红利 0.2 元（含税），送红股 0 股（含税），不以公积金转增股本。 2 | 第一节 | ...

Group 1 - The core viewpoint is that Fuan Pharmaceutical (300194.SZ) has some raw material drug products exported to the EU market, but the company primarily focuses on the domestic market, with overseas market revenue being relatively low [1] Group 2 - The company disclosed in its 2024 annual report that revenue by region indicates a dominant reliance on the domestic market [1] - The overseas market revenue accounts for a small proportion of the total revenue [1]

资金流向方面，今日主力资金净流入1002.79万元，占比成交额2.34%。其中，超大单净流入245.82万 元、占成交额0.57%，大单净流入756.97万元、占成交额1.77%，中单净流出流入1247.14万元、占成交 额2.91%，小单净流出2249.93万元、占成交额5.26%。 金融界消息 截至2025年8月15日收盘，福安药业（300194）报收于4.9元，下跌0.41%，换手率9.11%， 成交量88.22万手，成交金额4.28亿元。 福安药业最新一期业绩显示，截至2025一季报，公司营业总收入4.68亿元、同比减少42.22%，归属净利 润6904.90万元，同比减少43.63%，扣非净利润6568.48万元，同比减少43.80%，流动比率2.011、速动比 率1.269、资产负债率26.84%。 天眼查商业履历信息显示，福安药业(集团)股份有限公司，成立于2004年，位于重庆市，是一家以从事 医药制造业为主的企业。企业注册资本118971.2382万人民币，实缴资本17342万人民币。公司法定代表 人为汪天祥。 通过天眼查大数据分析，福安药业(集团)股份有限公司共对外投资了17家企业，参与招投 ...

Core Viewpoint - The industrial hemp sector experienced a significant surge on December 12, driven by news that former President Trump is considering reclassifying marijuana's danger level, which could lower its regulatory status [1] Market Performance - Fu'an Pharmaceutical rose over 15% - Rhine Biology hit the daily limit up - Morning Light Bio increased nearly 7% - Kang En Bei and Fu Ri Electronics both rose around 6% [1] U.S. Market Reaction - U.S. cannabis stocks saw strong performance on Monday: - Canopy Growth surged over 26% - Tilray Brands jumped over 40% - Cronos Group increased by more than 14%, reaching a 52-week high [1] Industrial Hemp Overview - Industrial hemp is characterized by a tetrahydrocannabinol (THC) content of less than 0.3% and does not exhibit psychoactive effects - Its seeds, flowers, leaves, stalks, and roots can be utilized in textiles, food, daily chemicals, and pharmaceuticals [1] Market Growth Forecast - According to Mordor Intelligence, the global industrial hemp market is projected to grow from $2.21 billion in 2023 to $4.97 billion by 2028 - This represents a compound annual growth rate (CAGR) of 17.56% over the next five years [1]

Core Viewpoint - The A-share market saw a collective rise in industrial hemp concept stocks, driven by potential regulatory changes regarding cannabis classification in the U.S. [1][2] Group 1: Stock Performance - Fu'an Pharmaceutical (300194) increased by 15.02%, with a total market capitalization of 63.77 billion [2] - Rhine Biology (002166) reached a 10% limit up, with a market cap of 68.23 billion [2] - Morning Light Biology (300138) rose by 6.38%, with a market cap of 69.32 billion [2] - Dezhan Health (000813) saw a 4.39% increase, with a market cap of 94.79 billion [2] - Shunhao Co. (002565) and Kang En Bei (600572) increased by 3.65% and 3.25%, with market caps of 90.42 billion and 120 billion respectively [2] Group 2: Regulatory News - The Washington Post reported that Trump expressed interest in reclassifying cannabis as a lower-risk drug during a fundraising dinner, which could simplify the buying and selling process of cannabis [3] - This potential regulatory change could make the multi-billion dollar cannabis industry more profitable [3]

每经AI快讯，8月12日，化学制药板块短线拉升，福安药业涨超10%，悦康药业、威尔药业、德展健 康、京新药业、振东制药等跟涨。 （文章来源：每日经济新闻） ...

Core Viewpoint - The company emphasizes its commitment to establishing a comprehensive and multi-layered collaboration framework with universities and research institutions since its inception [2] Group 1 - The company has engaged in partnerships with universities and research institutions as part of its broader strategy for external communication and collaboration [2]

Core Viewpoint - The company is developing a new high-end production facility for active pharmaceutical ingredients (APIs) with an expected annual capacity of 173.9 tons, but the timeline for completion is uncertain and depends on actual progress [1] Group 1 - The new facility aims to enhance the green and intelligent production of APIs [1] - The construction project is projected to take two years to complete [1] - The company acknowledges that the specific construction timeline may vary due to uncertainties [1]

金融界消息 截至2025年7月30日收盘，福安药业（300194）报收于4.74元，上涨1.07%，换手率6.46%， 成交量62.51万手，成交金额2.96亿元。 福安药业最新一期业绩显示，截至2025一季报，公司营业总收入4.68亿元、同比减少42.22%，归属净利 润6904.90万元，同比减少43.63%，扣非净利润6568.48万元，同比减少43.80%，流动比率2.011、速动比 率1.269、资产负债率26.84%。 资金流向方面，今日主力资金净流入1047.72万元，占比成交额3.54%。其中，超大单净流入1020.58万 元、占成交额3.44%，大单净流入27.15万元、占成交额0.09%，中单净流出流出337.97万元、占成交额 1.14%，小单净流出709.76万元、占成交额2.4%。 天眼查商业履历信息显示，福安药业(集团)股份有限公司，成立于2004年，位于重庆市，是一家以从事 医药制造业为主的企业。企业注册资本118971.2382万人民币，实缴资本17342万人民币。公司法定代表 人为汪天祥。 通过天眼查大数据分析，福安药业(集团)股份有限公司共对外投资了17家企业，参与招投标项 ...